Drugs & Targets FDA approves Imfinzi for locally advanced or metastatic biliary tract cancer September 09, 2022Vol.48 No.32
Drugs & Targets Calquence tablet formulation approved in the US across current indications, clinical data shows tablet bioequivalent to capsule September 09, 2022Vol.48 No.32
Drugs & Targets FDA accepts supplemental BLA for Genentech’s Polivy combination for previously untreated diffuse large B-cell lymphoma September 09, 2022Vol.48 No.32
Drugs & Targets BrainSpec earns special FDA designation for non-invasive virtual biopsy technology September 09, 2022Vol.48 No.32
Drugs & Targets FDA issues revised draft guidance on charging for investigational drugs under an IND application September 09, 2022Vol.48 No.32
Drugs & Targets MD Anderson and Empyrean to codevelop novel radiation therapy technologies September 09, 2022Vol.48 No.32
Drugs & Targets MD Anderson and Erasca form R&D collaboration in RAS/MAPK-driven cancers September 09, 2022Vol.48 No.32
Drugs & TargetsFree Lynparza approved by the EC as adjuvant treatment for high-risk breast cancer August 05, 2022Vol.48 No.31
Drugs & TargetsFree MD Anderson and TransCode Therapeutics collaborate to advance RNA therapies August 05, 2022Vol.48 No.31
